Our Pricing

Buy Semaglutide Online UK: Private Prescription Service

Published on: June 03, 2026

When you buy semaglutide online UK private prescription through Cured Pharmacy, you access the same clinical-grade medication used by the NHS, with transparent pricing from £79.00 and no waiting list. Our UK-registered prescribers assess your suitability through a free online consultation, typically completed in under three minutes, and genuine UK-licensed Wegovy pens are dispensed by our GPhC-registered pharmacy team led by superintendent pharmacist Tarun Kumar.

How Semaglutide Works for Weight Loss

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a naturally occurring hormone your body produces after eating [1]. When administered as a once-weekly subcutaneous injection, it acts on three distinct pathways: it slows gastric emptying so you feel fuller for longer, reduces appetite signals in the brain, and improves insulin sensitivity to help regulate blood glucose levels.

The STEP clinical trial programme demonstrated that semaglutide 2.4mg (the dose in Wegovy) produced an average 14.9% body weight reduction over 68 weeks when combined with lifestyle intervention, compared to 2.4% with placebo [1]. Participants also experienced improvements in cardiovascular risk markers including blood pressure, lipid profiles, and inflammatory markers such as C-reactive protein [2].

Private Semaglutide vs NHS: Understanding Your Options

The NHS provides semaglutide through specialist weight management services, but eligibility criteria are strict and waiting times often exceed 12 months in many regions. NHS guidelines typically require a BMI of 35 or above (or 32.5 for certain ethnic groups) plus at least one weight-related comorbidity, and patients must have documented evidence of previous weight loss attempts through diet and exercise programmes.

Private prescriptions through registered UK pharmacies offer the same MHRA-licensed medication with broader eligibility criteria, subject to prescriber approval. At Cured Pharmacy, our clinical team assesses patients with a BMI of 30 or above (or 27 with weight-related health conditions), following NICE guidance adapted for private care settings. You receive the identical Wegovy pens manufactured by Novo Nordisk that NHS patients use, with the same safety profile and clinical efficacy.

Who Can Access Private Semaglutide Prescriptions

Our UK prescribers evaluate multiple factors during your online consultation, including current BMI, medical history, concurrent medications, and previous weight loss attempts. Semaglutide may not be suitable if you have a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or diabetic retinopathy. Pregnant or breastfeeding individuals cannot use this medication, and you'll need to use effective contraception during treatment as weight loss may affect hormonal contraceptive absorption [3].

Semaglutide Dosing Schedule and What to Expect

Treatment follows a gradual dose escalation protocol designed to minimise gastrointestinal side effects whilst building therapeutic effect. You'll start with 0.25mg once weekly for four weeks, then increase to 0.5mg for four weeks, followed by monthly increases through 1mg, 1.7mg, and finally the maintenance dose of 2.4mg [4]. Each Wegovy pen is pre-filled and single-use, with a hidden needle that makes self-injection straightforward even for needle-anxious patients.

Most patients notice appetite reduction within the first two weeks, though significant weight loss typically becomes apparent after reaching the 1mg dose or higher. In the STEP-1 trial, the median time to achieve 5% weight loss was 12 weeks, and 10% weight loss occurred at a median of 28 weeks [1]. Your prescriber will monitor your progress and may adjust the escalation timeline if you experience persistent side effects or require additional time at lower doses.

Managing Side Effects: Clinical Insights from Dispensing Experience

Gastrointestinal effects are the most commonly reported side effects during semaglutide treatment, occurring in approximately 44% of trial participants compared to 24% receiving placebo [1]. These typically include nausea, diarrhoea, constipation, and occasional vomiting, with symptoms usually most pronounced in the 24-72 hours following each injection and diminishing as your body adapts to each dose level.

After dispensing semaglutide to thousands of UK patients, our clinical team has identified practical strategies that significantly improve tolerability. Injecting in the evening rather than morning means peak nausea coincides with sleep; eating smaller, more frequent meals rather than three large ones reduces gastric distension; avoiding high-fat foods for the first few days post-injection minimises delayed gastric emptying effects; and staying well-hydrated helps prevent constipation. If side effects remain troublesome, your prescriber may extend the time at your current dose before escalating, or temporarily reduce to the previous dose level.

When to Contact Your Prescriber

Seek immediate medical attention if you experience severe persistent abdominal pain (particularly if radiating to the back, which may indicate pancreatitis), visual changes, signs of thyroid lumps, or symptoms of severe dehydration such as reduced urination or dizziness. Contact your prescriber before your next dose if you have persistent vomiting lasting more than 24 hours, as this may require temporary treatment interruption and rehydration assessment.

Buy Semaglutide Online UK: How Cured Pharmacy Works

Our online consultation takes under three minutes and covers your medical history, current medications, weight loss goals, and any contraindications. You'll see transparent pricing before completing the assessment—Wegovy starts from £79.00 per pen, with the exact cost depending on your prescribed dose and supply duration. There are no hidden consultation fees, and you'll know your total cost upfront.

Once submitted, a UK-registered prescriber reviews your consultation within hours during business days. If approved, your prescription is sent electronically to our GPhC-registered dispensary (registration number 9012511), where our pharmacy team prepares your medication in 100% discreet packaging. We use temperature-controlled courier services to maintain the cold chain required for injectable biologics, with next-day delivery available across the UK. Each shipment includes your Wegovy pens, safety needles, a sharps bin, and comprehensive injection technique guidance.

Combining Semaglutide with Lifestyle Changes for Optimal Results

Clinical trial data consistently demonstrates that semaglutide works most effectively when combined with a reduced-calorie diet and increased physical activity [1]. The medication creates a physiological advantage by reducing hunger and food preoccupation, making it substantially easier to maintain the caloric deficit required for weight loss. In STEP-1, participants received counselling to reduce intake by 500 calories daily and increase physical activity to 150 minutes weekly [1].

From our clinical experience supporting UK patients through their weight loss journey, those who achieve the best outcomes typically focus on protein intake (aiming for 1.2-1.6g per kilogram of body weight daily to preserve lean muscle mass), resistance training at least twice weekly to maintain metabolic rate, and gradual sustainable changes rather than extreme restrictions. The appetite suppression from semaglutide means you'll naturally eat less, but choosing nutrient-dense foods ensures you meet micronutrient requirements despite lower overall intake. Our team can provide additional resources on optimising nutrition during GLP-1 treatment, and we recommend working with a registered dietitian for personalised guidance.

Long-Term Weight Maintenance After Semaglutide

The STEP-4 trial examined what happens when patients discontinue semaglutide after achieving weight loss, finding that participants regained approximately two-thirds of lost weight within one year of stopping [5]. This reflects the chronic nature of obesity as a medical condition rather than a medication failure. Many patients choose to continue maintenance therapy long-term, whilst others use semaglutide as a tool to establish sustainable habits before transitioning to lifestyle management alone. Your prescriber will discuss maintenance strategies based on your individual response and goals.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. [accessed 13 August 2026]
2. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., Wharton, S., & STEP 5 Study Group. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. [accessed 13 August 2026]
3. Novo Nordisk Limited. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance [TA875]. [accessed 13 August 2026]
5. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., & STEP 4 Investigators. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. [accessed 13 August 2026]
6. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-4 Investigators. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Semaglutide is a prescription-only medicine and individual results may vary based on adherence to treatment and lifestyle modifications.